GlassScriptPhysician profile
Donna R Dillard
NPI 1801819198
$8,880.02
in general payments reported to CMS, 2019-2025
47 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $1,135 · 2021: $1,424 · 2022: $1,271 · 2023: $1,307 · 2024: $1,125 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,541 · Entertainment: $12.78 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,541.21 |
| Entertainment | $12.78 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,435.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,232.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $742.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $653.43 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $580.54 | 2020-2024 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $575.73 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Allergan, INC. | $404.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $364.33 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.57 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $247.83 | 2019-2023 | |
| Amgen INC. | $208.43 | 2019-2024 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $201.78 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $181.39 | 2019-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $171.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $165.87 | 2023-2025 | Rexulti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Dillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.